River 2 Renal Corp

River 2 Renal Corp is a pre-clinical stage biotechnology company focused on developing novel therapies for renal diseases, specifically targeting cellular senescence. The company's technology is based on the research of Dr. Michael S. Goligorsky at New York Medical College, focusing on the role of p16INK4a-positive senescent cells in the progression of chronic kidney disease (CKD). By utilizing senolytic approaches, River 2 Renal aims to clear these harmful cells to restore kidney function and prevent disease progression. The company is part of a series of "River" entities managed in collaboration with RiverVest Venture Partners to advance specific therapeutic assets. Its programs represent a potential breakthrough in treating the underlying causes of kidney failure rather than just managing symptoms.